GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

Home・Elenco Azioni・Novo Nordisk A-S (Class B)

Novo Nordisk A-S (Class B)

Chiusa

288.45 1.26

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

286.85

Massimo

289.85

Metriche Chiave
By Trading Economics
Entrata	22B 49B
Vendite	18B 97B
P/E Media del settore	10.403 49.701
EPS	10.91
Rendimento da dividendi	4.09
Margine di Profitto	50.15
Dipendenti	67,900
EBITDA	32B 69B

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+9.53% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	4.09% 2.39%
Utili prossimi	5 ago 2026
Prossima data del' Ex Dividendo	13 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	8.6B 1.3T
Apertura precedente	287.19
Chiusura precedente	288.45

Novo Nordisk A-S (Class B) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 mag 2026, 15:48 UTC

Acquisizioni, Fusioni, Takeovers

Novo Nordisk to Sell Parkinson's Cell Therapy to Startup Cellular Intelligence

6 mag 2026, 07:30 UTC

Utili

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

6 mag 2026, 06:19 UTC

Utili

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

18 mag 2026, 13:10 UTC

Discorsi di Mercato

Utili

Novo Nordisk Report Shows Bright Spots Amid Price Pressure -- Market Talk

12 mag 2026, 12:05 UTC

Azioni calde

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12 mag 2026, 10:51 UTC

Azioni calde

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12 mag 2026, 09:42 UTC

Utili

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

12 mag 2026, 09:08 UTC

Azioni calde

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

11 mag 2026, 20:30 UTC

Utili

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

7 mag 2026, 09:30 UTC

Utili

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 mag 2026, 12:36 UTC

Utili

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 mag 2026, 10:53 UTC

Azioni calde

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 mag 2026, 10:12 UTC

Utili

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 mag 2026, 09:58 UTC

Utili

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

6 mag 2026, 09:35 UTC

Azioni calde

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 mag 2026, 08:13 UTC

Discorsi di Mercato

Utili

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

6 mag 2026, 07:43 UTC

Discorsi di Mercato

Utili

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

6 mag 2026, 07:00 UTC

Utili

Novo Nordisk Shares Rise 5.5% After 1Q Results

6 mag 2026, 06:34 UTC

Utili

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

6 mag 2026, 06:26 UTC

Utili

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

6 mag 2026, 06:26 UTC

Utili

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

6 mag 2026, 06:24 UTC

Utili

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

6 mag 2026, 06:20 UTC

Utili

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

6 mag 2026, 06:19 UTC

Utili

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

6 mag 2026, 06:13 UTC

Utili

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

6 mag 2026, 06:13 UTC

Utili

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

6 mag 2026, 06:12 UTC

Utili

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

6 mag 2026, 05:43 UTC

Utili

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

6 mag 2026, 05:42 UTC

Utili

Novo Nordisk: Total Prescriptions For Wegovy Pill in 1Q Reached Around 1.3M

6 mag 2026, 05:40 UTC

Utili

Novo Nordisk: First Wegovy Pill Launches Outside U.S. Expected During 2H26

Confronto tra pari

Modifica del prezzo

Novo Nordisk A-S (Class B) Previsione

Obiettivo di Prezzo

By TipRanks

9.53% in crescita

Previsioni per 12 mesi

Media 1,162.73 DKK 9.53%

Alto 1,550 DKK

Basso 720 DKK

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Novo Nordisk A-S (Class B) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Novo Nordisk A-S (Class B) - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.